Please login to the form below

Not currently logged in
Email:
Password:

Dr Ulf Jungnelius joins Oasmia Pharmaceuticals

He becomes senior medical advisor

Oasmia Pharmaceuticals Dr Ulf JungneliusOasmia Pharmaceuticals has appointed Dr Ulf Jungnelius as its new senior medical advisor.

He brings over 40 years of experience in oncology clinical research and development to the Uppsala, Sweden-based firm, having held leading positions in oncology at Eli Lilly, Pfizer and Takeda.

Most recently, Dr Jungnelius served as vice president, CR&D oncology at Celgene and continues serve as a partner for Healthcom, a healthcare technology company based in the US.

Julian Aleksov, executive chairman of Oasmia, said: “We are thrilled to add Dr Ulf Jungnelius, an individual with a very strong therapeutic area expertise and who has been a key driver in taking oncology blockbusters to regulatory approval and commercial success, to the Oasmia Pharmaceutical team.”

Meanwhile, Oasmia also announced Anders Lundin's resignation as chief financial officer.

Lundin joined the oncology drug developer in 2014, having previously served as head of finance at Galderma, a Swiss dermatology firm.

He will leave the company to pursue other business opportunities on 31 March.

5th February 2016

From: Research

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

PME Jan cover
AstraZeneca’s focus on diagnosing and managing chronic kidney disease
People living with chronic kidney disease are in urgent need of new and improved approaches to diagnosis and care...
Delphi Technique Virtual Co-creation: A Customer Story
How a client leveraged the Delphi technique to co-create a consensus statement and algorithm using virtual touchpoints....
AI healthcare
Three ways AI will change healthcare in the next decade
Looking forward, there is no doubt that AI will continue to take centre stage in global healthcare initiatives...

Infographics